Protein kinase C enzymes play an important role in signal transduction, regulation of gene expression and control of cell division and differentiation. The fsI and bII isoenzymes result from the alternative splicing of the PKCb gene (PRKCB1), previously found to be associated with autism. We performed a family-based association study in 229 simplex and 5 multiplex families, and a postmortem study of PRKCB1 gene expression in temporocortical gray matter (BA41/42) of 11 autistic patients and controls. PRKCB1 gene haplotypes are significantly associated with autism (P < 0.05) and have the autistic endophenotype of enhanced oligopeptiduria (P < 0.05). Temporocortical PRKCB1 gene expression was reduced on average by 35 and 31% for the PRKCB1-1 and PRKCB1-2 isoforms (P < 0.01 and < 0.05, respectively) according to qPCR. Protein amounts measured for the PKCbII isoform were similarly decreased by 35% (P = 0.05). Decreased gene expression characterized patients carrying the 'normal' PRKCB1 alleles, whereas patients homozygous for the autism-associated alleles displayed mRNA levels comparable to those of controls. Whole genome expression analysis unveiled a partial disruption in the coordinated expression of PKCb-driven genes, including several cytokines. These results confirm the association between autism and PRKCB1 gene variants, point toward PKCb roles in altered epithelial permeability, demonstrate a significant downregulation of brain PRKCB1 gene expression in autism and suggest that it could represent a compensatory adjustment aimed at limiting an ongoing dysreactive immune process. Altogether, these data underscore potential PKCb roles in autism pathogenesis and spur interest in the identification and functional characterization of PRKCB1 gene variants conferring autism vulnerability.
Introduction
Autism is a severe neuropsychiatric disorder characterized by impaired language, communication and social skills, and by repetitive and stereotypic behaviors. 1 Family and twin studies support strong genetic contributions to this disease. 2 However, the heterogeneity of clinical symptoms and the complexity of underlying pathogenetic processes have until now undermined efforts to achieve reproducible genotype-phenotype correlations. On one hand, the phenotypic expression of autism-predisposing genes spans from minimal autistic traits to full-blown autism, identifying a broad clinical entity referred to as 'autism-spectrum disorder' (ASD). 2, 3 On the other hand, the genetic underpinnings of autism encompass significant interindividual heterogeneity, numerous contributing loci, epistasis and likely gene-environment interactions. 2 Incomplete penetrance (that is, individuals carrying autism genes, but not fulfilling diagnostic criteria for the 'affected' status) and phenocopies (individuals carrying no genetic predisposition and fulfilling diagnostic criteria for 'autism' solely due to environmental factors) further decrease the statistical power of genetic analyses by introducing false-negative and false-positive 'affection status' definitions. In this complex scenario, the probability of success can be maximized by employing in parallel both genetic analyses and postmortem assessments of brain gene expression patterns. This strategy can indeed promote a better understanding of single-gene contributions to complex disorders, as recently demonstrated for the MET gene in autism. 4, 5 Several lines of evidence suggest that autism should be viewed as a multiorgan systemic disorder with a prenatal onset. On one hand, autism does not solely affect the central nervous system (CNS), despite encompassing obvious neurodevelopmental components: systemic signs and symptoms include macrosomy, 6 excessive intestinal permeability and nonspecific enterocolitis, [7] [8] [9] immune dysreactivity 9 and renal oligopeptiduria. 10 On the other hand, the neurodevelopmental mechanisms underlying the CNS abnormalities found in postmortem studies, which include reduced programmed cell death and/ or increased cell proliferation, and altered neuronal migration, differentiation and synaptogenesis, with the exception of the latter, are all active prenatally, especially during the first trimester of pregnancy. 2, 11, 12 Indeed, many children later diagnosed with ASD display motor abnormalities 13 and/or excessive body growth 6 already on the day of birth or in early neonatal life. Therefore, genes characterized by an early onset of expression and encoding proteins involved in the control of cell division, differentiation and migration can represent attractive candidates for autistic disorder even if their tissue distribution patterns are not necessarily restricted to the CNS.
The PRKCB1 gene, located in human ch. 16p11.2, represents an interesting locus displaying expression patterns not restricted to the CNS and previously found associated with autism. 14 In general, protein kinase C enzymes play an important role in signal transduction, regulation of gene expression and control of cell division and differentiation. The alternative splicing of PRKCB1 generates two mRNA isoforms named PRKCB1-1 and PRKCB1-2, yielding the two PKCb isoenzymes bI and bII. Interestingly, either or both isoforms are expressed in the districts most affected in autistic disorder, namely the CNS, immune system, digestive tract and kidney. In particular, brain PRKCB1 is expressed in hippocampus, striatum, suprachiasmatic nucleus and cerebellar granule cells, where PKCbI influences circadian rhythms, learning and memory, whereas PKCbII is involved in fear conditioning. [15] [16] [17] [18] [19] In the immune system, PKCb isoenzymes play a critical role in B-cell receptor-mediated responses, T-cell migration and cytokine secretion, dendritic cell differentiation and monocyte and macrophage functioning. [20] [21] [22] [23] [24] [25] In the gut, PKCbI and bII are expressed by epithelial cells, where they regulate intestinal permeability and cell proliferation, respectively. [26] [27] [28] In the kidney, both PKCb isoforms are expressed by mesangial cells and play a major role in diabetic nephropathy and albuminuria, possibly through oxidative stress. [29] [30] [31] Interestingly, many of the non-neural signs and symptoms that often accompany autism strikingly overlap with the pathophysiological roles played by PKCb isoforms in districts outside of the CNS.
The chromosomal region encompassing the PRKCB1 locus was initially identified using a direct identityby-descent mapping method as one of seven regions linked to autism, each spanning only between 0.75 and 4.0 Mb. 14 The same study described an association between PRKCB1 gene variants and autism both in Caucasian-Americans and in Mexican-Americans, albeit with the two ethnic groups carrying vulnerability alleles marked by different haplotypes.
14 This result was later not replicated in an Irish sample (see Discussion). 32 Still, the presence of a significant genetic association in two different ethnic groups, coupled with the functional involvement of PRKCB1 in many pathophysiological processes potentially underlying disease-related endophenotypes, spur interest into additional studies of PRKCB1 in autism. In accordance with the strategy outlined above and previously employed successfully with the MET gene, 4, 5 this study was designed to replicate the initial genetic findings in an independent sample and to extend these studies by (a) assessing PRKCB1 gene expression in postmortem temporocortical gray matter (BA41/42) from 11 pairs of ASD patients and sex-, age-, and postmortem intervalmatched controls; (b) correlating PRKCB1 gene expression with PRKCB1 genotypes in these postmortem brain samples and (c) assessing the functional consequences of dysregulated PRKCB1 gene expression using genomewide expression array technology. Our results confirm the existence of a significant association between PRKCB1 gene variants and autism, describe for the first time an association with the biochemical endophenotype defined by enhanced urinary peptide excretion rates, detect a significant reduction of PRKCB1 mRNA and protein levels in postmortem autistic brains, reveal a dysregulation of gene expression patterns delineating a possible compensatory adjustment aimed at limiting an ongoing immune dysreactive process and identify a lack of downregulation in gene expression as the most likely functional correlate of PRKCB1 alleles conferring autism vulnerability.
Subjects and methods
Subjects recruited for the family-based association study A total of 229 simplex and 5 multiplex families with a non-syndromic autistic proband were recruited for this study. The composition of our clinical sample, encompassing 239 autistic patients and 90 unaffected siblings, is summarized in Table 1 . Demographic and clinical characteristics as well as diagnostic screening procedures used to exclude syndromic autism have been previously described. 33 Briefly, patients fulfilling DSM-IV diagnostic criteria for Autistic Disorder 1 were screened for non-syndromic autism using magnetic resonance imaging, electroencephalogram, audiometry, urinary aminoacid, and organic acid measurements, cytogenetic and fragile-X testing. Patients with dysmorphic features were excluded even in the absence of detectable cytogenetic alterations. Patients with sporadic seizures (that is, < 1 every 6 months) were included; patients with frequent seizures or focal neurological deficits were excluded. Autistic behaviors were assessed using the official Italian version of the Autism Diagnostic Observation Schedule 34 and the Autism Diagnostic Interview-Revised (ADI-R); 35 adaptive functioning was assessed using the Vineland Adaptive Behavior Scales; I.Q. was determined using either the Griffith Mental Developmental Scales, the Coloured Raven Matrices, the Bayley Developmental Scales or the Leiter International Performance Scale. 33 All parents gave written informed consent for themselves and for their children, using the consent form approved by the I.R.B. of University Campus Bio-Medico (Rome, Italy).
Genotyping
Four single nucleotide polymorphisms (SNPs) located in intron 2 of the PRKCB1 gene were genotyped, including the three SNPs previously found associated with autism in Caucasians, 14 and one additional SNP located approximately 18 kb upstream (Table 2A) . SNPs were genotyped using the TaqMan method (Applied Biosystems, Foster City, CA, USA), with probes purchased from the manufacturer and used according to the manufacturer's guidelines. DNA was PCR-amplified with denaturation at 95 1C for 10 min, 40 cycles at 92 1C for 15 s, 60 1C for 1 min and 72 1C for 45 s, followed by elongation at 72 1C for 5 min. TaqMan assays were then read on a 7900HT Fast 
Biochemical and morphological endophenotypes
Blood samples for 5-HT levels were obtained from all family members and centrifuged within 20 min of venipuncture at 140 g for 25 min at 4 1C; 1 ml of supernatant (that is, platelet-rich plasma) was stored at À80 1C and assessed by high-performance liquid chromatography, as described. 36 Urinary peptide excretion analysis was performed by high-performance liquid chromatography on the first morning from urine samples of all family members, diluted to 250 nm creatinine, as described. 10 The total area of peaks under the 215 nm absorption curve in the peptide region following the hippuric acid peak was calculated and expressed in mm 2 . Excess peptiduria was defined on the basis of previously published normality ranges determined in population controls. 10 Head circumference was measured in autistic patients and unaffected siblings by trained physicians using a non-stretchable plastic measuring tape graded in millimeters, placed over the maximum fronto-occipital head perimeter; head circumference measures were transformed into percentiles using sex-and age-specific standard tables, as described. 6 
Statistical analyses
Hardy-Weinberg equilibrium was tested using the w 2 statistic, as implemented by the HAPLOVIEW software (available at http://www.broad.mit.edu/mpg/ haploview/index.php) 37 for the total sample and by HWE (available at http://linkage.rockefeller.edu) to analyze separately autistic patients, mothers, fathers, and unaffected siblings. Family-based single-marker and haplotype association tests were performed using the FBAT statistic (S = STX, where T is the phenotypic trait and X the marker value), as implemented by the FBAT software package (available at http://www. biostat.harvard.edu/~fbat/fbat.htm), under an additive model (option Àe). 38 The FBAT statistic stems from the transmission/disequilibrium test (TDT), where preferential allelic transmission from heterozygous parents to affected offspring is tested by applying the (bÀc) 2 /(b þ c) statistics and the w 2 ('McNemar test'). 39 Quantitative traits were analyzed by quantitative TDT, as implemented by the FBAT software, 38 with T as the quantitative trait of interest (instead of a dichotomic affected/unaffected status as in the TDT), and by parametric or nonparametric ANOVA, based on genotype distributions. The HBAT command in FBAT was also employed to estimate haplotype frequencies and linkage disequilibrium (LD) from pedigree data. 38 TDT analyses controlling for quantitative covariates were performed using the multinomial logistic regression model underpinning the retrospective likelihood method implemented by the Unphased software package, applying the 'confounder' and 'uncertain haplotypes' options. 40 To minimize the impact of confounding variables, such as drug therapy, puberal status and differential growth rates, quantitative analyses were restricted to patients aged < 11 years and not taking selective 5-HT reuptake inhibitors for 5-HT blood levels, and to patients aged < 16 years for head size, as in our previous studies. 6, 33, 36 Statistical analyses were performed merging together our 210 Italian and 24 CaucasianAmerican families (Table 1) after population structure analyses provided no evidence of major genetic dyshomogeneity in a subset of 155 Italian and 24 Caucasian-American patients randomly chosen one per family, genotyped at 90 unlinked SNPs distributed genome-wide and analyzed using the Structure program, as described (see Supplementary Methods). 41 Data are expressed as mean ± s.e.m., except for head circumference and urinary peptide excretion rates, expressed as median percentile±interquartilic range. Two-tail P-values are reported, with significance level set at P < 0.05. No correction for repeated measures was implemented in our family-based association study, because (a) it has been undertaken to replicate previously published positive findings; 14 (b) we document the relative genetic homogeneity of our Italian and Caucasian-American patients; (c) the four SNPs used to define a single haplotype, previously found associated with autism, 14 are characterized by short intermarker physical distances, significant LD and non-independent marker segregation (see Results section); (d) many endophenotypic measures assessed in the same autistic patients are non-independent. Instead, statistical significance was set at P < 0.01 for tests of Hardy-Weinberg equilibrium (that is, < 0.05/5 comparisons), whereas nominal P-values are reported for exploratory genotype-phenotype correlations regarding clinical measures, due to the large number of clinical variables tested.
Patient brain tissue information
Postmortem studies were performed using frozen brain tissue samples dissected from the superior temporal gyrus (BA 41/42) of 11 patient-control pairs, obtained through the Autism Tissue Program from the Maryland NICHD Brain Tissue Center and the Harvard Brain Tissue Resource Center. This neocortical region was chosen because it hosts welldocumented structural and functional abnormalities in autism. 42 These tissue samples largely overlap with those employed in our recent study of the MET pathway. 5 Clinical and demographic information, family history and autopsy reports were obtained from the Autism Tissue Program web site (www. atpportal.org) and are summarized in Table 3 . The presence of mental retardation (MR) was defined on the basis of a full-scale IQ < 70. ASD cases fulfilled DSM-IV diagnostic criteria, 1 confirmed using the Autism Diagnostic Interview-Revised (ADI-R). 35 Controls were selected to match patients on sex, age ( ± 2 years, with the exception of ± 4 years in pair nine) and postmortem interval, as much as possible (Table 3) . Pharmacological therapy from the last available report, dating back to less than a year before death.
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Expression analysis by real-time PCR Total RNA was extracted from all 11 case-control pairs (Table 3 ) using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to standard methods, and RNA quality was checked using a Bioanalyzer (Agilent, Santa Clara, CA, USA). Reverse transcription was performed using the QuantiTect Reverse Transcription kit (QIAGEN, Hilden, Germany), employing random hexamers as primers. The amount of each specific cDNA was measured using an iQ5 Multicolor Real-Time PCR Apparatus according to a standard DDCt SYBR Green protocol (BioRad, Hercules, CA, USA). 43 CyclophilinA cDNA was measured in parallel with both PRKCB1 isoforms and used as a standard normalizer. The following isoform-specific primers were designed: PRKCB1-1F AGACACCTCCA ACTTCGACAA; PRKCB1-1R CAACGATGGAGTTTG CATTC; PRKCB1-2F AAGCTCAACGGCTATTGTGG; PRKCB1-2R GCCATCTGCATAATCCCATC; cyclophilinA-F GCAGACAAGGTCCCAAAG; cyclophilinA-R GAAGTCACCACCCTGACAC. Statistical significance was calculated using the Wilcoxon test.
Western blotting
Western blotting was performed on 8 of the 11 casecontrol pairs (no. 1-8 in Table 3 ) because of limited tissue availability. Sixty micrograms of protein extract were diluted in 2 Â SDS/loading sample buffer, boiled for 5 min, loaded onto a 5% stacking/7.5% separating polyacrylamide gel, run at 100 V for 2 h, and transferred onto a nitrocellulose membrane at 350 mA for 90 min. Membranes were blocked with 5% milk in 0.1% Tris-buffered saline Tween-20 (TBS-T) for 1 h, washed 3 Â 10 min in 0.01% TBS-T, incubated overnight at 4 1C with primary antibody against PKCbII (sc-13149, Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted 1:600 in 0.05% TBS-T with 5% milk. Following 3 Â 10 min washes in 0.01% TBS-T, membranes were incubated for 1 h at room temperature with horseradish peroxidase-conjugated goat antimouse IgG (sc-2005, Santa Cruz Biotechnology) diluted 1:5000 in 0.1% TBS-T and 3% milk. Following 3 Â 10 min washes in 0.01% TBS-T, proteins were visualized using the enhanced chemiluminescent (ECL) detection method and Hyperfilm (Amersham Biosciences, Piscataway, NJ, USA). Densitometry was performed using the VersaDoc model 4000 imaging system (BioRad).
To control for protein loading, membranes were washed 3 Â 10 min in 0.01% TBS-T, and incubated with mouse AC15 anti-b-actin monoclonal antibody (A5441, Sigma-Aldrich, St Louis, MO, USA) diluted 1:5000, and with goat antimouse IgG (AP124P, Chemicon International, Temecula, CA, USA) diluted 1:5000. Data are presented as PKCbII normalized to b-actin (mean±s.d.). Statistical significance was determined using the Wilcoxon test.
Microarray analysis
Total RNA isolation, reverse transcription and in vitro transcription were performed, as previously described. 44 RNA samples from six case-control pairs (no. 2, 4, 5, 7, 8 and 11 in Table 3) provided RIN values > 6.9 and were thus hybridized to HG_U133plus2 human Affymetrix GeneChips, with segmentation analysis performed using Microarray Analysis Suite 5.0 (MAS5). Normalization of data was performed using GC-RMA. 45 Data were converted to a linear scale by log2 transformation, with gene clustering performed using Genes@Work software. 46 Gene set analysis was performed using Gene Set Enrichment Analysis (GSEA) software (version 2) 47 with array probe sets collapsed to gene symbol and gene sets generated from Biocarta gene set list (converted from probe set list with manual curation), using ASD versus control phenotypes and 1000 permutations/ analysis. Statistical significance was calculated using a paired Student's t-test. False discovery rate threshold in GSEA was set at q < 0.05. 48 Correlation analyses were performed by Pearson r.
Results
PRKCB1 gene variants are associated with autism
The four SNPs, located in intron 2 of the PRKCB1 locus, are in Hardy-Weinberg equilibrium both in the entire data set of 795 individuals (Supplementary  Table S1 ), and also when analyzing separately 239 autistic patients, 234 mothers, 232 fathers, and 90 unaffected siblings. The same four SNPs are also in LD, as summarized in Table 2B ; their LD pattern in our sample is superimposable to the LD pattern found by the International HapMap Project in their Caucasian CEPH population (that is, Utah residents with ancestry from northern and western Europe; see www.hapmap.org).
PRKCB1 haplotypes display a significant association with autism, as shown in Table 4A (whole marker permutation test, P < 0.05 after 32271 iterations). Haplotype 2-2-2-1 is transmitted from heterozygous parents to their autistic offspring significantly more often than expected by chance (P = 0.007), at the expense of the complementary haplotype 1-1-1-2 (Table 4A) . Unaffected siblings display the opposite trend, with an undertransmission of haplotype 2-2-2-1 reaching a borderline P = 0.053 (Supplementary  Table S2 ) and yielding a highly significant difference in transmission rates between autistic and nonautistic offspring (Z = 16.23, P&lt;0.00001). Despite their lower statistical power, single-marker FBAT analyses also support the existence of LD between the most 5 0 SNP, rs3785392 and the PRKCB1 gene variant contributing to autism vulnerability (Table 4B ). Superimposable trends in allelic transmission rates are found in Italian and CaucasianAmerican families analyzed separately. No parentof-origin effect is consistently present (data not shown). Preliminary analyses performed on clinical signs and symptoms suggest a possible influence of PRKCB1 alleles on the 'presence/absence of verbal or motor stereotypies at intake,' with the 'risk' allele significantly blunting stereotypic behaviors. In fact, stereotypies were noticed at intake in 17/26 (65. 
PRKCB1 gene variants are associated with enhanced oligopeptiduria in autism
Macrocephaly/macrosomy, hyperserotoninemia and enhanced peptiduria are among the best-characterized morphological and biochemical endophenotypes in autism. 6, 10, 36 Performing a quantitative TDT, as implemented by the FBAT program, 38 we found a significant association between parent-to-autistic offspring transmission rates of PRKCB1 gene variants marked by the two most 5 0 SNPs, rs3785392 and rs3785387, and urinary peptide excretion rates (Table 5and Supplementary Table S3) . ANOVAs based on genotype distributions provide further evidence of semidominant effects for 'risk' allele 2 at SNP rs3785387, associated with enhanced peptiduria (genotype 1/1, n = 20, 218.5 ± 251 mm Table S4) . Incorporating peptiduria as a covariate into haplotypic and single-marker analyses for affection status essentially did not change their outcome: the whole marker permutation test for haplotypic analysis yielded a P = 0.054, while single-marker analyses for rs3785392 and rs3785387 yielded P = 0.02 and 0.11, respectively (compare with Tables 4A and 4B). These results indicate that the overtransmission of PRKCB1 gene variants to autistic offspring is largely, though not entirely, independent of peptiduria.
PRKCB1 gene expression is significantly decreased in postmortem brains of autistic patients PRKCB1 gene expression is significantly decreased in the temporal neocortex of ASD patients compared to their matched controls. PRKCB1 mRNA levels are decreased by 26% according to oligonucleotide DNA microarray analysis (pairwise t-and rank-tests P < 0.05). Using isoform-specific primers, quantitative PCR unveils 35 and 31% mean reductions for the PRKCB1-1 and PRKCB1-2 isoforms, yielding P < 0.01 and < 0.05, respectively (Figure 1 ). In particular, mRNA levels are decreased by 25% or more in seven ASD patients compared to controls, whereas the remaining four patients displayed comparable levels ( Figure 1 ). Given the superimposable trends displayed by the two mRNA isoforms, decreased expression patterns were confirmed at the protein level assessing the PKCbII isoform only. Mean PKCbII amounts measured using Western blot and normalized by b-actin were found decreased by 35% (P = 0.05), a result entirely superimposable to the decrease recorded at the mRNA level using quantitative PCR. A consistent decrease in PKCbII levels was found in seven out of eight ASD individuals, compared to their matched controls (Figure 2 ).
'Risk' alleles at SNPs rs3785392 and rs3785387 are associated with an inability to downregulate PRKCB1 gene expression in postmortem brains of autistic patients Genomic DNA was extracted from the same neocortical specimens used to assess PRKCB1 gene expression and the same four SNPs were genotyped (Supplementary Table S5 ). PRKCB1-1 and PRKCB1-2 mRNA levels were then correlated with genotypes at SNPs rs3785392 and rs3785387, previously found associated with autism and/or peptiduria (see above). Controls homozygous for 'risk' allele 2 at both SNPs displayed small, nonsignificant increases in PRKCB1 gene expression levels for both isoforms (Figure 3) . Instead, autistic patients carrying the 2/2 genotype had mRNA levels comparable to those of controls, whereas patients with the 1/1 or 1/2 genotypes underwent a profound and significant downregulation of gene expression (Mann-Whitney U tests, P < 0.05; Figure 3 ). These results indicate that homozygosity for 'risk' allele 2 at SNPs rs3785392 and rs3785387 is associated with an inability to downregulate neocortical PRKCB1 gene expression in autistic brains. These genotype-phenotype correlations certainly did not stem from a skewed distribution of confounding factors, such as MR or seizures (that is, history of seizures, seizure-related death or use of antiepileptic drugs at the time of death; Table 3 ) because 'risk' alleles at SNPs rs3785392 and rs3785387 were evenly distributed among patients with and without MR or seizures. Furthermore, risk alleles were equally associated with higher PRKCB1 mRNA levels in the Table S3 for SNPs rs196002 and rs1873423. Figure 1 Significant decrease in PRKCB1 gene expression in the temporal neocortex of 11 autism-spectrum disorder (ASD) patients, relative to their matched controls. Levels of mRNA encoding the PRKCB1-1 and PRKCB1-2 isoforms, assessed by qPCR using isoform-specific primers, are equally decreased. Bars indicate mean values; the hyphenated line corresponds to no case-control difference in mRNA levels. *P < 0.05 and **P < 0.01 for patients versus controls.
PRKCB1 gene and autistic disorder C Lintas et al presence of either seizures or MR (data not shown). However, the downregulation of PRKCB1 gene expression may be especially pronounced in autistic patients with MR and/or with seizures. For example, among five patients with seizures, three individuals carrying the 1/1 or 1/2 genotypes at SNP rs3785392 displayed PRKCB1-2 mRNA levels 61.3% lower compared to two patients carrying the 2/2 genotype; among patients without a history of seizures, this same mean difference was reduced to 21.5% (n = 2 and 4 for 2/2 or other genotype carriers, respectively). These analyses must be, however, viewed as merely exploratory, because no contrast here reaches statistical significance due to small sample sizes.
Disrupted coordination of brain gene expression patterns involving PRKCB1 in autism
We hypothesized that deficits in PKCb expression would putatively lead to a dysregulation in PKCbdependent transcript networks and to significant Table S5 for complete genotype list. *P < 0.05.
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downstream alterations in neuronal function. To test this hypothesis, we explored the temporocortical expression of PRKCB1-related transcript networks in autistic patients and matched control subjects using oligonucleotide DNA microarray analysis. First, the microarrays employed in this study encompass two independent probe sets for PRKCB1 (227817_at and 209685_s_at), which consistently demonstrated superimposable expression differences between postmortem autistic and control brains (ALR = À0.44 and À0.46, respectively). In addition, the two probe sets displayed high positive correlations (r = 0.98 and 0.86 for autistics and controls, respectively), further validating our findings. Next, in a data-driven approach, we identified 1009 gene transcripts that were highly coregulated with PKCb in the brain of control subjects (r > 0.9). In addition, we identified 131 transcripts that (a) displayed correlation differences of Dr AUTÀCON X0.8 with PRKCB1 between patients and controls (r AUT À r CON ) and (b) reported a significant expression difference between the autistics and control postmortem temporal cortices (|ALR| > 0.585 and P < 0.05 in pairwise t-test). Among these, 71 genes showed a positive correlation with PRKCB1 levels in ASD cases and an opposite or unchanged trend in controls, including the kainate 2 ionotropic glutamate receptor (GRIK2) and the neuronal/epithelial high affinity glutamate transporter (SLC1A1). Even more interestingly, 60 mRNAs that were positively correlated with PRKCB1 levels in controls showed a loss of the positive correlation with PRKCB1 levels in ASD cases. Among others, these included genes encoding multiple neurodevelopmentally relevant molecules (for example, FGF2 and FGF-R1) and cytokines (for example, TGFb2) (Figure 4) .
Finally, we explored a knowledge-based correlation between mRNA levels of PRKCB1 and genes whose expression has been shown to be under direct or indirect PKCb control. 23, 24, 26, [28] [29] [30] [31] These results revealed that coordinated expression patterns are lost for several cytokines and enzymes involved in oxidative stress, maintained to a large extent for others, and entirely preserved for extracellular matrix proteins (Table 6 ). In addition to the loss of correlation with PKCb transcript levels, many of these genes also displayed significant expression differences between autistic and control brains, including TGFb2, MCP1, collagen IV and fibronectin 1 ( Table 6) .
Discussion
This study (a) replicates in an independent sample the positive association between PRKCB1 gene variants and autism previously reported by Philippi et al.;
14 (b) extends family-based genetic findings by demonstrating a significant association also with a biochemical endophenotype characterized by enhanced oligopeptiduria; (c) provides novel evidence showing significantly reduced PRKCB1 mRNA and protein levels, as well as disrupted PKCb-related gene expression patterns in postmortem neocortical tissue samples of autistic patients compared to age-, sex-, and postmortem interval-matched controls and (d) identifies a blunted downregulation of PRKCB1 gene expression in postmortem brains as the functional correlate of PRKCB1 'risk' alleles associated with autism. These functional abnormalities in PRKCB1 gene expression nicely parallel genetic evidence of PRKCB1 gene contributions to autism pathogenesis and lend further support to PKCb involvement in the pathogenetic processes underlying autistic disorder.
Our family-based linkage/association study essentially confirms the existence of a significant association between autism and PRKCB1 gene variants marked in Caucasians by polymorphisms located in intron 2. The C-G-T haplotype found associated with autism in Caucasians by Philippi et al.
14 is identical to our risk haplotype for rs3785387 and rs196002, whereas it differs at SNP rs1873423. Considering the progressive decrease of LD going from 5 0 to 3 0 in this region (Table 2B) , and the much stronger association of 5 0 markers both with autism and with oligopeptiduria in this study (Table 4 and Supplementary Table  S3 ), it seems likely that haplotypes associated with autism in our sample and in Caucasian-Americans (Table 2B) , whereas D 0 values range only from 0.045 to 0.195 in the Irish sample. 32 These population genetic differences can alone explain why polymorphisms employed in this and in previous studies 14, 32 are apt to mark the autism liability conferring PRKCB1 gene variant in the Italian and Caucasian-American populations, but are uninformative in the Irish population.
Our postmortem study has conclusively demonstrated a significant decrease in PRKCB1 gene expression (Figures 1 and 2 ). Potential confounding factors are inevitably intermingled with autism in our postmortem sample, as they are at the phenotypic level. Approximately 75% of autistic patients indeed have MR and 25% a positive history of seizures. 2 In our postmortem sample, MR and seizures could modulate PRKCB1 allelic effects on gene expression, but do not appear to produce a spurious association. Instead, this significant downregulation in gene expression is interestingly associated with 'normal' PRKCB1 alleles, not with alleles conferring autism liability. A thorough mutational search for non-conservative, coding mutations and for splice junction variants previously provided negative results.
14 Recently, a 593 kb region located in human ch. 16p11.2 has been shown to undergo a recurrent microdeletion or a reciprocal microduplication in approximately 1% of autistic patients. 49, 50 These genomic rearrangements, typically de novo but in some cases also inherited, are unlikely to explain our expression and association findings: they are 5 Mb centromeric to the PRKCB1 locus, their low frequency could hardly skew transmission rates to the extent encountered in our association study and, most importantly, we found no evidence of genomic rearrangements involving the PRKCB1 gene itself in five of the same brain specimens employed in this study and displaying here variable decreases in PRKCB1 gene expression (R Sacco, S Levy, P Levitt, AM Persico et al., article in preparation). Therefore, this PRKCB1 'risk' allele most likely consists in an intronic variant that inactivates a negative-feedback loop on gene expression. The exact mechanism underlying this allelic effect is currently being investigated. In general, it is not unusual for large introns, such as intron 2 of the PRKCB1 gene, which spans approximately 150 kb, to produce totally intronic noncoding RNAs, especially frequent among members of the Gene Ontology 'Regulation of transcription' gene category. 51 Alternatively, single base pair changes can indeed affect gene expression by creating or deleting an intronic response element, enhancer or repressor, 52 as recently demonstrated for a single base pair change causing the loss of an Sp1 response element in the MET gene promoter. 4 Regardless of the underlying mechanism, the association of PRKCB1 'risk' alleles with a blunted adaptive downregulation of gene expression seemingly fits with several converging lines of evidence. First, PRKCB1 gene expression was strongly decreased in several patients, and particularly in those carrying one or two 'normal' PRKCB1 alleles (Figures 1-3) . Interestingly, PKCb downregulation produced by either homologous recombination in PRKCB1 gene knockout mice or by selective pharmacological blockade is associated with an immunosuppression, encompassing decreased monocyte recruitment and migration, reduced oxidative stress and blunted gene expression for chemokines such as ICAM-1, MCP-1 and TGFb. [29] [30] [31] 53 Conversely, several in vitro models indicate that the selective activation of both PKCb isoforms is critical to sustain oxidative stress. 54, 55 These proinflammatory effects of PKCb sharply contrast with the decrease in PRKCB1 gene expression reported here, because the very same neocortical brain samples employed in this study display enhanced oxidative stress (L Palmieri, AM Persico et al., submitted) and increased immune gene expression. 56 The latter results are in agreement with previous studies demonstrating enhanced oxidative stress in autism 57 and an ongoing immune reaction in a set of postmortem brain tissue samples of autistic patients largely non-overlapping with ours, and in the CSF of autistic children collected in vivo.
58 Figure 4 Correlation of PRKCB1 mRNA expression with levels of mRNAs encoding the glutamate receptor GRIK2, the neuronal glutamate transporter SLC1A1, FGF2 and TGFb2, in six autistic patients (red) and matched controls (green). Pearson r coefficients and ALR values are reported.
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Many genes expressing chemokines are either directly or indirectly upregulated by PKCb-induced phosphorylation: [29] [30] [31] 53 the decrease in PRKCB1 gene expression documented in our study, and the increased expression of immune genes like TGFb2 (Figure 4 ) clearly argue against PRKCB1 driving this ongoing immune activation in patient samples. On the contrary, a compensatory decrease in PRKCB1 gene expression occurring in ASD patients to buffer an inappropriate activation of the immune system seemingly represents the most plausible scenario. In the latter case, any genetic variant reducing the sensitivity of PRKCB1 gene expression to this negative-feedback loop would result in an even more persistent immune activation, sustaining oxidative stress, and fostering developmental damage during early pregnancy. It will thus be extremely important to identify the exact sequence variant conferring autism vulnerability and to determine its functional correlates in vitro. Only then it will be possible to tie the current results into the broader picture of autism pathogenesis, also because, despite its intended adaptive value, the decrease in PRKCB1 gene expression recorded in most autistic brains could still play a negative role, for example by blocking the physiological relocation of both FMRP and Fmr1 mRNA in dendrites following activation of metabotropic glutamate receptors. 59 The significant association recorded here between PRKCB1 gene variants and enhanced urinary peptide excretion rates increases confidence in the reliability of our results and spurs further interest in the underlying pathophysiology. Functional PRKCB1 promoter variants have been shown to be associated with diabetic nephropathy and albuminuria, 60,61 mediated by increased renal oxidative stress, production of fibrotic cytokines such as TGFb, and consequently increased glomerular permeability. [29] [30] [31] Also of interest is the potential gene-gene interaction with APOE e2 alleles, which contribute to the development and progression of diabetic nephropathy 62, 63 and are preferentially transmitted to autistic children in our sample. 64 A potential parallel between 'leaky kidney' and 'leaky gut' syndromes is suggested by an in vitro study demonstrating that PKCb and calcium are both necessary for oxidative stress to yield abnormal permeability in monolayers of human intestinal Caco-2 cells. 26 This effect, linking calcium, 65 oxidative stress, 57 and PKCb to the stability of epithelial cytoskeleton in the gut, could conceivably explain the abnormally elevated intestinal permeability present in many autistic patients and the subsequent activation of the immune system due to the absorption of the first foreign dietary peptides recognized by the gut immune system as 'non-self', namely casein and gluten. 7 Our current phenotypic data set does not allow us to directly test this hypothesis. Nonetheless, our sample encompasses 106 families with mixed genotypes at SNP rs3785392, 7 families whose members all carry the 'normal' 1/1 genotype, and 10 families entirely composed of 2/2 'risk genotype' carriers. A positive history of 'food allergies' in unaffected family members of the autistic proband was self-reported in 11/106 (11.6%) 'mixed genotype' families, 1/7 (14.3%) 'normal genotype' families and 4/10 (40.0%) 'risk genotype' families, respectively (w 2 = 7.097, 2 d.f., P < 0.05). This analysis is merely suggestive, but spurs interest into specific hypothesisdriven studies aimed at determining whether there is a pathophysiological overlap between the PKCbdependent processes responsible for a 'leaky kidney' and the mechanisms contributing to the 'leaky gut' syndrome in autism.
In summary, this study confirms the existence of a genetic association between PRKCB1 gene variants and autism, demonstrates a significant association between PRKCB1 gene variants and the quantitative endophenotype of oligopeptiduria, shows a prominent reduction in PRKCB1 gene expression in the temporal neocortex of autistic patients compared to matched controls, demonstrates that alleles conferring autism vulnerability are associated with a lack of downregulation in PRKCB1 gene expression, and provides evidence of a partially uncoordinated expression of PRKCB1 and several PKCb-dependent genes involved in neurodevelopment and immune functions. These expression changes can currently be best interpreted as a compensatory adjustment aimed at hampering a dysregulated immune response affecting the CNS of autistic patients. The negative-feedback loop mediating this compensatory adjustment is 
